U.K. Seeks Regulatory Edge on Health by Investing in Medical Simulation

According to AI TIMES, the U.K. Health Economics Research Institute analyzed on October 21 that increasing investment in medical AI and computer simulation could secure 37,282 more years of healthy life over the next five years and cut NHS costs by about KRW 2 trillion. The assessment projected the effect of fully incorporating in silico technologies into regulatory and validation systems during the drug and medical device development process. The article noted that this technology could reduce dependence on animal testing and help secure evidence for groups that are difficult to represent in actual clinical settings. It also said the expected benefits will not materialize automatically, but will require sufficient investment, model validation, and trust-building by regulators. In particular, because this is a point at which standards for how far computer-based evidence should be accepted in safety and efficacy evaluations are being formed, the article said the country that refines them first could gain an edge in international regulatory discussions and industrial competitiveness. In the end, the article views medical simulation not as a simple development tool, but as a driver that could reshape health finance, R&D methods, and the regulatory order together.